Edict Acquisition (Tables) (Edict Acquisition [Member])

6 Months Ended

Jun. 30, 2012

Edict Acquisition [Member]

Business Acquisition [Line Items]

Schedule Of Acquisition-Date Fair Value Of The Consideration Transferred

	Amount
Cash paid for equity	$	20,659
Contingent purchase price liabilities	11,641		(1)
Cash paid for assumed indebtedness	4,300
Total consideration	$	36,600

(1) Contingent purchase price liabilities represent subsequent milestone payments related to successful FDA inspection of the Par Formulations manufacturing facility and ANDA filings.  All contingent purchase price liabilities are expected to be paid within 18 months of the acquisition date.

Schedule Of Purchase Price Allocation

	As of  February 17, 2012
Cash and cash equivalents	$	273
Inventories	192
Prepaid expenses and other current assets	1,143
Property, plant and equipment	5,370
Intangible assets	1,850
Total identifiable assets	8,828
Accounts payable	995
Accrued expenses and other current liabilities	200
Deferred tax liabilities	938
Total liabilities assumed	2,133
Net identifiable assets acquired	6,695
Goodwill	29,905
Net assets acquired	$	36,600

Schedule Of Operating Results

	Six Months ended		Six Months ended
(In thousands, except per share data)	June 30, 2012		June 30, 2011
Total revenues	$	565,805	$	457,140
Income (loss) from continuing operations	23,738		(102,783		)
Income (loss) from continuing operations per diluted share	$	0.64	$	(2.88	)